Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome?

Journal of Clinical Apheresis

Volumn 24, Issue 5, 2009, Pages 209-214

  Gore, Ethan McCaleb ^a   Jones, Benjamin Scott ^a   Marques, Marisa B ^b  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

ADAMTS 13; Atypical hemolytic uremic syndrome; Gemcitabine; Therapeutic plasma exchange; Thrombotic microangiopathy

Indexed keywords

CAPECITABINE; CARBOPLATIN; CREATININE; DOXORUBICIN; FIBRIN; FUROSEMIDE; GEMCITABINE; HAPTOGLOBIN; LACTATE DEHYDROGENASE; NAVELBINE; PACLITAXEL; PAMIDRONIC ACID; SPIRONOLACTONE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; BREAST CANCER; CASE REPORT; DIALYSIS; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; GLOMERULUS FILTRATION RATE; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY BIOPSY; KIDNEY FAILURE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PATHOGENESIS; PERIPHERAL EDEMA; PLASMAPHERESIS; PROTEINURIA; REVIEW; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; THROMBUS;

ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MIDDLE AGED; PLASMA EXCHANGE;

EID: 70449560501     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20213     Document Type: Review

References (24)

1. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347:589-600.
2. Allford S, Hunt BJ, Rose P, Machin SJ. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anemias. Br J Haematol 2003;120:556-573.
3. Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol 2001;14:437-454.
4. Blackall DP, Marques MB. Hemolytic uremic syndrome. Am J Clin Pathol 2004;121:S81-S88.
5. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12: 29-34.
6. Brodowicz T, Breiteneder S, Wiltschke C, Zielinski CC. Gemcitabine-induced hemolytic uremic syndrome: a case report. J Natl Cancer Inst 1997;89:1895-1896.
7. Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 1999;85: 2023-2032.
8. Lhotta K, Kühr T, Rumpelt HJ, Wöll E, Thaler J, König P. Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy. Am J Nephrol 1999;19: 590-593.
9. Serke S, Riess H, Oettle H, Huhn D. Elevated reticulocyte count: a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report. Br J Cancer 1999;79: 1519-1521.
10. Flombaum CD, Mouradian JA, Casper ES, Erlandson RA, Benedetti F. Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine. Am J Kidney Dis 1999;33: 555-562.
11. Gross M, Hiesse C, Kriaa F, Coldwasser F. Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine. Anticancer Drugs 1999;10: 533-566.
12. Dumontet C, Morschhauser F, Solal-Celigny P, Bouafia F, Bourgeois E, Thieblemont C, Leleu X, Hequet O, Salles G, Coiffier B. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br J Haematol 2001;113:772-778.
13. Walter RB, Joerger M, Pestalozzi BC. Gemcitabine-associated hemolytic-uremic syndrome. Am J Kidney Dis 2002;40: E16.
14. Citarrella P, Gebbia V, Teresi M, Miceli S, Sciortino G, Vaglica M, Pizzardi N, Palmeri S. Hemolytic uremic syndrome after chemotherapy with gemcitabine and taxotere: a case report. Anticancer Res 2002;22:1183-1186.
15. Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade J, Pusztai L, Hortobagvi G. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 2003;21:3249-3254.
16. Humphreys BD, Sharman JP, Henderson JM, Clark JW, Marks PW, Rennke HG, Zhu AX, Magee CC. Gemcitabine-associated thrombotic microangiopathy. Cancer 2004;100: 2664-2670.
17. Müller S, Schütt P, Bojko P, Nowrousian MR, Hense J, Seeber S, Moritz T. Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution. Ann Hematol 2005;84:110-114.
18. Saif MW, McGee PJ. Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature. J Pancreas 2005;6:369-374.
19. Lewin S, Mutch D, Whitcomb B, Liapsis H, Herzog T. Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin. Gynecologic Oncology 2005;97:228-233.
20. De Smet D, Jochmans K, Neyns B. Development of thrombotic thrombocytopenic purpura after a single dose of gemcitabine. Ann Hematol 2008;87:495-496.
21. Kalra N, Kad R, Osama S. Gemcitabine-induced hemolytic uremic syndrome in ovarian carcinoma. Int J Clin Oncol 2007; 12:385-387.
22. Boeck S, Geiger S, Schulz C, Heinemann V. Hemolytic-uremic syndrome associated with gemcitabine treatment for metastatic pancreatic cancer. J Clin Gastroenterol 2008;42:551-552.
23. Zupancic M, Shah PC, Shah-Khan F. Gemcitabine-associated thrombotic thrombocytopenic purpura. Lancet Oncol 2007;8: 634-641.
24. Porta C, Danova M, Riccardi A, Bobbio-Pallavicini E, Ascari E. Cancer chemotherapy-related thrombotic thrombocytopenic purpura: biological evidence of increased nitric oxide production. Mayo Clin Proc 1999;74:570-574.